Online first
Short communication
Published online: 2024-07-17
Lipid goal achievement one month after myocardial infarction: Observational real-world study from Polish population
Abstract
Not available
References
- Visseren FLJ, Mach F, Smulders YM, et al. ESC Scientific Document Group, ESC Scientific Document Group, ESC Scientific Document Group, ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
- Byrne RA, Rossello X, Coughlan JJ, et al. ESC Scientific Document Group, ESC Scientific Document Group, ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38): 3720–3826.
- Banach M, Penson PE, Vrablik M, et al. ACS EuroPath Central & South European Countries Project. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021; 166: 105499.
- Nowowiejska-Wiewióra A, Wita K, Mędrala Z, et al. Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program. Kardiol Pol. 2023; 81(4): 359–365.
- Cecha P, Chromik A, Piotrowska I, et al. Assessment of application of the new 2019 European Society of Cardiology/ European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias in daily clinical practice - one center study. Folia Med Cracov. 2021; 61(3): 43–54.
- Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018; 379(22): 2097–2107.
- Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376(18): 1713–1722.
- Ray K, Molemans B, Schoonen W, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology. 2020; 28(11): 1279–1289.
- Jankowski P, Kozieł P, Setny M, et al. Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey. J Clin Med. 2021; 10(16).
- Lewek J, Niedziela J, Desperak P, et al. Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data. J Am Heart Assoc. 2023; 12(18): e030414.
- Mackinnon ES, Leiter LA, Wani RJ, et al. Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study. Cardiol Ther. 2024; 13(1): 205–220.
- Ferrières J, Lautsch D, Bramlage P, et al. Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome. Arch Cardiovasc Dis. 2020; 113(10): 617–629.
- Nicholls SJ. PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives. Kardiol Pol. 2023; 81(2): 115–122.
